ELICIT-PLANT
11.3.2024 10:01:30 CET | Business Wire | Press release
Elicit Plant, a pioneering and rapidly expanding agri-biotech company, announces the appointment of the renowned scientist and a leader in the ag-tech industry, Slavica Djonovic, Ph.D. as Chief Scientific Officer (CSO). An author of more than 20 patent family applications in the space of biomolecular and biological innovations for plant stress, her appointment reflects Elicit Plant's commitment to accelerating the transition towards sustainable and environmentally friendly agriculture. Slavica Djonovic's mission is to propel the company to a new level of innovation by developing cutting-edge solutions to help farmers worldwide combat water stress and scarcity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240308898928/en/
Slavica Djonovic, Chief Scientific Officer (Photo: Elicit Plant)
A remarkable scientific and leadership career
With over two decades of ag-tech experience, Slavica Djonovic is a respected scientific leader in the field of research and development of biological products for agriculture, especially in broad acre crops.
Slavica holds a Master of Science from Colorado State University, a Ph.D. from Texas A&M University, and she has completed her postdoctoral training at Massachusetts General Hospital and Harvard Medical School.
Her entrepreneurial spirit led her to be one of the founding scientists of Indigo Ag, a Boston-based agricultural biotechnology company. There, she played a key role as Director of Product Science, making significant contributions to product discovery, development, intellectual property, regulatory, and the launch of the company's first five microbial products. At Joyn Bio, a synthetic biology Agtech company in Boston (US), she served as Senior Director by establishing the disease control program and initiating the regulatory science approach, thus solidifying her reputation as a leader in agrotechnological innovation.
An expertise aligned with Elicit Plant's high ambitions
With a track record of over 20 patent applications in innovations related to plant stress, the vast majority of which have been internationally granted, Slavica Djonovic brings to Elicit Plant cutting-edge technical expertise and a unique strategic vision, precisely at a time when Elicit Plant is preparing to enter a new critical period of growth and innovation.
"Faced with the challenges posed by climate change, it is imperative that our agricultural sector quickly embraces innovative solutions to ensure a healthy and sustainable future for all. I am honored to join Elicit Plant, a booming pioneer in the agricultural sector, empowering farmers to effectively tackle climate upheavals. Elicit Plant's proprietary technology, EliTerra®, the consistent performance of its products internationally, and its team driven by a clear mission, are impressive," states Slavica Djonovic, CSO of Elicit Plant.
"In her new role as Chief Scientific Officer, Slavica will be tasked with amplifying Elicit Plant's scientific influence and accelerating the development of our EliTerra® Technological platform. Slavica brings with her a wealth of knowledge and unparalleled experience that will be essential levers for our evolution. We are convinced that under her scientific leadership, Elicit Plant will reach a new milestone in developing innovative solutions for agriculture," concludes Jean-François Déchant, CEO of Elicit Plant.
For more information: https://www.elicit-plant.com/press-resources/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240308898928/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
Speech Processing Solutions Launches Philips SpeechLive Legal AI Assistant for Faster, More Accurate Legal Document Creation5.8.2026 15:37:00 CEST | Press release
The new SpeechLive Legal AI Assistant reduces the administrative burden on legal professionals through customizable document drafting powered by speech recognition tuned for legal terminology Speech Processing Solutions, the global leader in AI-assisted professional dictation and documentation solutions sold under the Philips brand, today announced the Philips SpeechLive Legal AI Assistant. The new solution transforms voice recordings, dictation and uploaded sources into structured, ready-to-review legal documents, helping legal professionals work faster while retaining control of the final draft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805997413/en/ The new Philips SpeechLive Legal AI Assistant is designed for turning conversations into ready-to-review legal document drafts. SpeechLive Legal significantly reduces the time needed to transform voice input into structured legal documentation, delivering consistent an
Corpay Cross-Border Named the Official FX Partner of Ultimate Sevens5.8.2026 15:31:00 CEST | Press release
Providing access to currency risk management and cross-border payments solutions Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into an agreement with Ultimate Sevens, a new global rugby sevens championship backed by BIA Sports Group launching in August 2026. Under the agreement, Corpay becomes Ultimate Sevens exclusive and Official Foreign Exchange (FX) Partner, along with being an Ultimate Sevens Playmaker. As the Championships’ exclusive foreign exchange partner, Corpay Cross-Border will provide Ultimate Sevens with comprehensive FX risk management solutions to help manage foreign exchange exposure from its day-to-day business activities. Corpay Cross-Border’s award-winning platform will also enable Ultimate Sevens to manage global payments through a single point of access. “Corpay Cross-Border is thrilled to be named the exclusive and official FX partner of Ultimate Sevens,” said Brad Loder,
TestMu AI Makes Samsung Galaxy Z Fold8 and Galaxy Z Fold8 Ultra Available on Real Device Cloud Ahead of Retail Launch5.8.2026 14:30:00 CEST | Press release
Developers can test websites and mobile apps on Samsung's newest foldables, running Android 17, before the devices reach customers TestMu AI (formerly LambdaTest), the world's first full-stack Agentic AI Quality Engineering platform, announced that the Samsung Galaxy Z Fold8 and Galaxy Z Fold8 Ultra are now available for testing on its Real Device Cloud. Both devices, unveiled at Samsung's Galaxy Unpacked event, run Android 17 with One UI 9 and are accessible for live testing and automation before retail units reach customers. The launch generation introduces a testing challenge new to the Galaxy Z Fold line. The Galaxy Z Fold8 unfolds into a portrait-oriented 7.6-inch display, while the Galaxy Z Fold8 Ultra, the first Ultra model in the Z series, unfolds into a landscape-oriented 8.0-inch display. Two devices that share a name, a chipset, and an operating system present layouts with opposite orientations, which means an interface validated on one can break on the other. "Samsung has i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
